Indeed, recent findings reported that bromodomains (BRD) extra terminal (BET) inhibitors (BETi), which act inhibiting C-MYC transcription, are strongly cytotoxic in primary B-ALL cell lines and xenografts [76] and in pediatric primary B-ALL samples [77]. Here, MYC is linked to acute lymphoblastic leukemia.